Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.

Currently, only 21% of Wall Street analysts have Palantir ranked a "buy". This makes Palantir the lowest recommended, best ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

On Wednesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $301.44 which represents a slight increase of $2.60 or 0.87% from the prior close of $298.84. The stock opened at $306 and ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares closed yesterday at $298.84.

However, on the same day, Jefferies maintained a Buy rating on Amgen (NASDAQ: AMGN). Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly ...